Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis
The role of the mesenchymal stromal cell- (MSC-) derived secretome is becoming increasingly intriguing from a clinical perspective due to its ability to stimulate endogenous tissue repair processes as well as its effective regulation of the immune system, mimicking the therapeutic effects produced b...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2020/4356359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546973109977088 |
|---|---|
| author | Selma Maacha Heba Sidahmed Shana Jacob Giusy Gentilcore Rita Calzone Jean-Charles Grivel Chiara Cugno |
| author_facet | Selma Maacha Heba Sidahmed Shana Jacob Giusy Gentilcore Rita Calzone Jean-Charles Grivel Chiara Cugno |
| author_sort | Selma Maacha |
| collection | DOAJ |
| description | The role of the mesenchymal stromal cell- (MSC-) derived secretome is becoming increasingly intriguing from a clinical perspective due to its ability to stimulate endogenous tissue repair processes as well as its effective regulation of the immune system, mimicking the therapeutic effects produced by the MSCs. The secretome is a composite product secreted by MSC in vitro (in conditioned medium) and in vivo (in the extracellular milieu), consisting of a protein soluble fraction (mostly growth factors and cytokines) and a vesicular component, extracellular vesicles (EVs), which transfer proteins, lipids, and genetic material. MSC-derived secretome differs based on the tissue from which the MSCs are isolated and under specific conditions (e.g., preconditioning or priming) suggesting that clinical applications should be tailored by choosing the tissue of origin and a priming regimen to specifically correct a given pathology. MSC-derived secretome mediates beneficial angiogenic effects in a variety of tissue injury-related diseases. This supports the current effort to develop cell-free therapeutic products that bring both clinical benefits (reduced immunogenicity, persistence in vivo, and no genotoxicity associated with long-term cell cultures) and manufacturing advantages (reduced costs, availability of large quantities of off-the-shelf products, and lower regulatory burden). In the present review, we aim to give a comprehensive picture of the numerous components of the secretome produced by MSCs derived from the most common tissue sources for clinical use (e.g., AT, BM, and CB). We focus on the factors involved in the complex regulation of angiogenic processes. |
| format | Article |
| id | doaj-art-cbf19dfa069a4679bd513e699933a22f |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-cbf19dfa069a4679bd513e699933a22f2025-02-03T06:46:33ZengWileyStem Cells International1687-966X1687-96782020-01-01202010.1155/2020/43563594356359Paracrine Mechanisms of Mesenchymal Stromal Cells in AngiogenesisSelma Maacha0Heba Sidahmed1Shana Jacob2Giusy Gentilcore3Rita Calzone4Jean-Charles Grivel5Chiara Cugno6Deep Phenotyping Core, Sidra Medicine, Doha 26999, QatarAdvanced Cell Therapy Core, Sidra Medicine, Doha 26999, QatarDeep Phenotyping Core, Sidra Medicine, Doha 26999, QatarAdvanced Cell Therapy Core, Sidra Medicine, Doha 26999, QatarAdvanced Cell Therapy Core, Sidra Medicine, Doha 26999, QatarDeep Phenotyping Core, Sidra Medicine, Doha 26999, QatarAdvanced Cell Therapy Core, Sidra Medicine, Doha 26999, QatarThe role of the mesenchymal stromal cell- (MSC-) derived secretome is becoming increasingly intriguing from a clinical perspective due to its ability to stimulate endogenous tissue repair processes as well as its effective regulation of the immune system, mimicking the therapeutic effects produced by the MSCs. The secretome is a composite product secreted by MSC in vitro (in conditioned medium) and in vivo (in the extracellular milieu), consisting of a protein soluble fraction (mostly growth factors and cytokines) and a vesicular component, extracellular vesicles (EVs), which transfer proteins, lipids, and genetic material. MSC-derived secretome differs based on the tissue from which the MSCs are isolated and under specific conditions (e.g., preconditioning or priming) suggesting that clinical applications should be tailored by choosing the tissue of origin and a priming regimen to specifically correct a given pathology. MSC-derived secretome mediates beneficial angiogenic effects in a variety of tissue injury-related diseases. This supports the current effort to develop cell-free therapeutic products that bring both clinical benefits (reduced immunogenicity, persistence in vivo, and no genotoxicity associated with long-term cell cultures) and manufacturing advantages (reduced costs, availability of large quantities of off-the-shelf products, and lower regulatory burden). In the present review, we aim to give a comprehensive picture of the numerous components of the secretome produced by MSCs derived from the most common tissue sources for clinical use (e.g., AT, BM, and CB). We focus on the factors involved in the complex regulation of angiogenic processes.http://dx.doi.org/10.1155/2020/4356359 |
| spellingShingle | Selma Maacha Heba Sidahmed Shana Jacob Giusy Gentilcore Rita Calzone Jean-Charles Grivel Chiara Cugno Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis Stem Cells International |
| title | Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis |
| title_full | Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis |
| title_fullStr | Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis |
| title_full_unstemmed | Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis |
| title_short | Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis |
| title_sort | paracrine mechanisms of mesenchymal stromal cells in angiogenesis |
| url | http://dx.doi.org/10.1155/2020/4356359 |
| work_keys_str_mv | AT selmamaacha paracrinemechanismsofmesenchymalstromalcellsinangiogenesis AT hebasidahmed paracrinemechanismsofmesenchymalstromalcellsinangiogenesis AT shanajacob paracrinemechanismsofmesenchymalstromalcellsinangiogenesis AT giusygentilcore paracrinemechanismsofmesenchymalstromalcellsinangiogenesis AT ritacalzone paracrinemechanismsofmesenchymalstromalcellsinangiogenesis AT jeancharlesgrivel paracrinemechanismsofmesenchymalstromalcellsinangiogenesis AT chiaracugno paracrinemechanismsofmesenchymalstromalcellsinangiogenesis |